Clinical experiences with testosterone therapy: prostate safety

References

• Jeffcoate SL, Brooks RV, Lim NY, et al. Androgen production in hypogonadal men. J Endocrinol 1967;37:401–11
   PubMedGoogle Scholar
• Griffin JE, Wilson JD. Disorders of the testes and the male reproductive tract. In Wilson JD, Foster DW, eds. Williams Textbook of Endocrinology. 1992:799–852
   Google Scholar
• Basaria S, Dobs AS. Risks versus benefits of testosterone therapy in elderly men. Drugs Aging 1999:131–42
   Google Scholar
• Jockenhoevel F. Male Hypogonadism, 1st edn. Bremen: Uni-Med, 2004:18
   Google Scholar
• Nieschlag E. Circadian rhythm of plasma testos- terone. In Aschoff J, Halberg F, eds. Chronobiological Aspects of Endocrinology. Stuttgart, New York: Schattauer Verlag, 1974
   Google Scholar
• Morley JE, Kaiser FE, Perry HM, et al. Long- itudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997;46:410–13
   PubMed Web of Science ®Google Scholar
• Gray A, Berlin JA, McKinlay JB, Longcope C. An examination of research design effects on the association of testosterone and male aging: results of a meta-analysis. J Clin Epidemiol 1991;44:671–84
   PubMed Web of Science ®Google Scholar
• Kley HK, Nieschlag E, Bidlingmaier F, Krus- kemper HL. Possible age-dependent influence of estrogens on the binding of testosterone in plasma of adult men. Horm Metab Res 1974;6:213–16
   PubMed Web of Science ®Google Scholar
• Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 1983;56:1278–81
   PubMed Web of Science ®Google Scholar
• Rhoden EL, Morgentaler A. Risks of testoster- one-replacement therapy and recommendations for monitoring. N Engl J Med 2004;350:482–92
   PubMed Web of Science ®Google Scholar
• Schow DA, Redmon B, Pryor JL. Male meno- pause. how to define it, how to treat it. Postgrad Med 1997;101:62–79
   PubMed Web of Science ®Google Scholar
• Davidson JM, Camargo CA, Smith ER. Effects of androgen on sexual behavior in hypogonadal men. J Clin Endocrinol Metab 1979;48:955–8
   PubMed Web of Science ®Google Scholar
• Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab 2000;85:2839–53
   PubMed Web of Science ®Google Scholar
• Bhasin S, Buckwalter JG. Testosterone supple- mentation in older men: a rational idea whose time has not yet come. J Androl 2001;22:718–31
   PubMedGoogle Scholar
• Matsumoto AM. Andropause: clinical implica- tions of the decline in serum testosterone levels with aging in men. J Gerontol A Biol Sci Med Sci 2002;57:M76–99
   PubMed Web of Science ®Google Scholar
• Bhasin S, Singh AB, Mac RP, et al. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommenda- tions for a standardized monitoring plan. J Androl 2003;24:299–311
   PubMed Web of Science ®Google Scholar
• Swerdloff RS, Wang C. Androgens and aging in men. Exp Gerontol 1993;28:435–46
   PubMed Web of Science ®Google Scholar
• Schroder FH, EORTC Genitourinary Group. Prostate cancer studies. Prog Clin Biol Res 1990; 357:73–81
   PubMedGoogle Scholar
• Morales A, Lunenfeld B. Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of the Interna- tional Society for the Study of the Aging Male. Aging Male 2002;5:74–86
   PubMedGoogle Scholar
• Gerstenbluth RE, Maniam PN, Corty EW, Seftel AD. Prostate-specific antigen changes in hypogo- nadal men treated with testosterone replacement. J Androl 2002;23:922–6
   PubMedGoogle Scholar
• Mohr BA, Feldman HA, Kalish LA, et al. Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study. Urology 2001; 57:930–5
   PubMedGoogle Scholar
• Miller LR, Partin AW, Chan DW, et al. Influence of radical prostatectomy on serum hormone levels. J Urol 1998;160:449–53
   PubMedGoogle Scholar
• Zhang PL, Rosen S, Veermachaneni R, et al. Association between prostate cancer and serum testosterone levels. Prostate 2002;53:179–82
   PubMed Web of Science ®Google Scholar
• Flores E, Bratoeff E, Cabeza M, et al. Steroid 5 alpha-reductase inhibitors. Mini Rev Med Chem 2003:225–37
   Google Scholar
• Occhiato EG, Guama A, Danza G, Serio M. Selective non-steroidal inhibitors of 5 alpha- reductase type 1. J Steroid Biochem Mol Biol 2004; 88:1–16
   PubMed Web of Science ®Google Scholar
• Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215–24
   PubMed Web of Science ®Google Scholar
• Slater S, Oliver RT. Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs Aging 2000;17:431–19
   PubMed Web of Science ®Google Scholar
• Huggins C, Stevens R, Hodges C. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941;43:209–23
   Google Scholar
• Swerdloff R, Wang C, Iranmanesh A, et al. Transdermal testosterone (T) gel is efficacious and safe in older compared to young men. Presented at The Endocrine Society’s 84th Annual Meeting, San Francisco, CA, June 19–22, 2002, abstr 472
   Google Scholar
• Swerdloff RS, Wang C. Three-year follow-up of androgen treatment in hypogonadal men: pre- liminary report with testosterone gel. Aging Male 2003;6:207–11
   Google Scholar
• Rhoden EL, Morgentaler A. Testosterone repla- cement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol 2003; 170 (6 Pt 1): 2348–51
   Google Scholar
• Meikle A, Arver S, Dobs AS, et al. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology 1997;49:191–6
   PubMed Web of Science ®Google Scholar
• Kenny AM, Prestwood KM, Gruman CA, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2001;56:M266–72
   PubMed Web of Science ®Google Scholar